Make next 10 years 'the decade of India': Piyush Goyal to pharma firms

Coining a new acronym, Goyal said the world today needs CURE - Cost-effective Uni­ve­rsal solutions through Research and Enterprise

Piyush goyal
Union Minister Piyush Goyal. Photo: PTI
Nikunj Ohri New Delhi
2 min read Last Updated : Feb 26 2021 | 12:06 AM IST
The past few years have been a golden period for health ca­re, and the industry should strive to make the next 10 ye­ars “the decade of India”, said Commerce and Industry Mi­n­ister Piyush Goyal on Thursday.
 
Till 2030, the entire world should be driven by Indian quality standards, regulatory processes, and manufacturing practices, he said at the International Conf­erence on Pharmaceuticals and Medical organised by industry body Ficci.
 
Coining a new acronym, he said the world today needs CURE — Cost-effective Uni­ve­rsal solutions through Research and Enterprise. “If we take it upon ourselves that India is going to cure the world, I see no limitations in our ability to aspire to bec­ome a world dominant leader in the field of medtech, pharmaceuticals, medical dev­i­ces, and health care providers.”
 
The country would alw­ays be indebted to the Indian pharma industry, often called the pharmacy of the world, for its contribution in fighting the Covid-19 pandemic, Goyal said. The three Vs that the industry has provided to the world, and to India — ventilators, vaccines, and the V-shaped recovery in India’s economy — are reflective of the industry’s strength.
 
WTO waiver for easy vaccine access
 
Goyal said India’s proposal at the World Trade Organi­zation (WTO) for trade-related asp­ects of intellectual property rights waiver to allow more countries to get equitable access to Covid-19 vaccine is getting support from other nations. India along with South Africa had introduced a proposal in October 2020 for waiving the intellectual property rights regime so that mo­re countries get equitable acc­ess to medicines, Goyal said.


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Piyush GoyalPharma industryCommerce ministry

Next Story